超声引导射频消融与甲状旁腺切除术治疗原发性甲状旁腺功能亢进的临床与经济评价:队列研究
该队列研究纳入123例原发性甲状旁腺功能亢进患者,经倾向性评分匹配后比较超声引导射频消融与甲状旁腺切除术,每组37对。射频消融组术后疼痛发生率更低(16.2% vs 40.5%),增量成本为负,更具成本效果。
要点
- 超声引导射频消融治疗原发性甲旁亢的治愈率与手术切除相当。
- 射频消融组术后疼痛发生率显著低于甲状旁腺切除术。
- 射频消融增量成本为负,是更具成本效果的非手术治疗选择。
局限性
- 单中心研究,样本量经匹配后较小(37对)。
- 回顾性设计可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To compare the clinical and economic effects of ultrasound (US)-guided radiofrequency ablation (RFA) with parathyroidectomy (PTX) for primary hyperparathyroidism (PHPT).
MATERIALS AND METHODS: From April 2014 to April 2021, 123 PHPT patients who received US-guided RFA or PTX were studied. Propensity score (PS) matching was used to balance the baseline data of the two groups. The rates of cure, recurrent and persistent PHPT, and complications were compared. A Chinese healthcare system perspective cost minimization analysis was conducted.
RESULTS: After PS matching, 37 patient pairs (1:1) were created for the two groups. Follow-up was 27.2 ± 10.6 months and 28.8 ± 16.1 months for the RFA and PTX groups, respectively. At the last follow-up, there was no evidence of differences regarding clinical cure rate between the two groups (RFA vs. PTX, 91.9% vs. 94.6%, p = 1.000). Recurrent PHPT did not develop in any patient. One patient in each group had persistent PHPT. The incidence of complications and side effects, except postoperative pain (RFA vs. PTX, 16.2% vs. 40.5%, p = 0.020), were no significant difference between the two groups (all, p > 0.05). The incremental cost was -$284.00; thus, RFA was more cost-effective. For patients with employee medical insurance or resident medical insurance, the incremental costs (RFA vs. PTX) were -$391.94 and -$49.43, respectively.
CONCLUSION: There were no significant differences in efficacy and safety between RFA and PTX. As the incremental cost for RFA compared with PTX was negative, RFA may be used as a more cost-effective nonsurgical treatment alternative for PHPT.
引用
- Chai, Dai, Xu, et al. Clinical and Economic Evaluation of Ultrasound-Guided Radiofrequency Ablation vs. Parathyroidectomy for Patients with Primary Hyperparathyroidism: A Cohort Study. Acad Radiol. 2023. PMID: 36966072. doi:10.1016/j.acra.2023.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。